The great ambivalence: factors likely to affect service user and public acceptability of the pharmacogenomics of antidepressant medication
Article first published online: 28 AUG 2008
© 2008 The Authors. Journal compilation © 2008 Foundation for the Sociology of Health & Illness/Blackwell Publishing Ltd
Sociology of Health & Illness
Volume 30, Issue 6, pages 944–958, September 2008
How to Cite
Barr, M. and Rose, D. (2008), The great ambivalence: factors likely to affect service user and public acceptability of the pharmacogenomics of antidepressant medication. Sociology of Health & Illness, 30: 944–958. doi: 10.1111/j.1467-9566.2008.01116.x
- Issue published online: 28 AUG 2008
- Article first published online: 28 AUG 2008
- 2003) Hope against hype: accountability in biopasts, presents and futures, Science Studies, 16, 3–21. (
- 1999) Effects of client interviewers on client reported satisfaction with mental health services, Psychiatric Services, 50, 961–3. , , and (
- 2003) Pharmaceutical industry is main influence in GP prescribing, British Medical Journal, 326, 301. (
- 2006) Europeans and biotechnology in 2005: patterns and trends., Eurobarometer, 64, 3, Brussels. , , , et al . (
- 2003) Patients’ ambivalence about taking antidepressants: a qualitative study, The Pharmaceutical Journal, 271, 516–18. and (
- 2004) The Politics of Personalised Medicine: Pharmacogenetics in the Clinic. Cambridge: Cambridge University Press. (
- 2003) The drugs don't work: expectations and the shaping of pharmacogenetics, Social Studies of Science, 33, 327–64. and (
- 2007) The Loss of Sadness: how Psychiatry Transformed Normal Sorrow into Depressive Disorder. Oxford: Oxford University Press. and (
- House of Commons (2005) The Influence of the Pharmaceutical Industry. Health Committee Fourth Report of Session 2004–2005 Volume I. London: The Stationery Office Limited.
- 1997) Speaking of Sadness: Depression, Disconnection, and the Meanings of Illness. Oxford: Oxford University Press. (
- 2006) Is it Me or my Meds? Living with Antidepressants. Cambridge: Harvard University Press. (
- 2005) Against Depression. New York: Penguin. (
- 2001) The distinction between mental and physical illness, The British Journal of Psychiatry, 178, 490–3. (
- 1994) The methodology of focus groups: the importance of interaction between research participants, Sociology of Health and Illness, 16, 1, 103–21. (
- 2002) The impact of pharmacogenomics and pharmacogenomics on drug discovery, Nature Reviews, 1, 463–9. (
- 2006) False Positive? The Commercial and Clinical Development of Pharmacogenetics. IGBis, SATSU, University of Nottingham. , , and (
- Medicines and Healthcare Products Regulatory Agency (2004) Selective serotonin reuptake inhibitor (SSRI) antidepressants – findings of the Committee on Safety of Medicines (CSM) Working Group. Annex A – prescribing trends for SSRIs and related antidepressants. London: MHRA.
- National Institute of Clinical Excellence (2003) Depression: Management of Depression in Primary and Secondary Care, Clinical Guideline 23. London: National Institute of Clinical Excellence.
- 2004) Pharmacogenomic testing: informed consent and the problem of secondary information, Bioethics, 18, 344–60. and (
- 2007) The diffusion of innovation: factors influencing the uptake of pharmacogenetics, Community Genetics, 10, 231–41. and (
- 2006) The political economy of hope: patients’ organisations, science, and biovalue, Biosocieties, 1, 289–305. (
- 2004) Pathways to psychiatric care and reform of the public health care system in Poland, European Psychiatry, 19, 168–71. and (
- 2007) A qualitative study of personalised medicine: public priorities and values. ‘Genetics and Society: Retrospects and Prospects’. CESAGen/CSG 4th International Conference, 26th–28th March 2007, The Royal Society, London. and (
- 2006) Patients’ and physicians’ perspectives on pharmacogenetic testing, Pharmacogenomics, 7, 49–59. , , , and (
- 2003) Patients’ perspectives on electroconvulsive therapy: systematic review, British Medical Journal, 326, 1363–6. , , , and (
- 2005) Psycho-pharmaceuticals in Europe. In Knapp, M., McDaid, D., Mossialos, E. and Thornicroft, G. (eds) Mental Health Policy and Practice across Europe. Maidenhead: Open University Press. (
- 2000) Pharmacogenomics and the practice of medicine, Nature, 405, 857–65. (
- 2003) Public attitudes about pharmacogenomics. In Rothstein, M.A. (ed.) Pharmacogenomics: Social, Ethical, and Clinical Dimensions. Hoboken, NJ: John Wiley and Sons. and (
- Royal Society (2005a) Personalised Medicines: Hopes and Realities. London: Royal Society.
- Royal Society (2005b) Pharmacogenetics: Dialogue. London: Royal Society.
- 2005) The historical development of mental health services in Europe. In Knapp, M., McDaid, D., Mossialos, E. and Thornicroft, G. (eds) Mental Health Policy and Practice across Europe. Maidenhead: Open University Press. (
- 2000) Doing Qualitative Research. London: SAGE. (
- 2004) Tailored medicine: whom will it fit? Ethics of patient and disease stratification, Bioethics, 18, 322–43. , and (
- 2002) The Noonday Demon: an Anatomy of Depression. London: Vintage Books. (
- 2004) Antidepressant use by US adults soars, Washington Post 3rd December, A15. (
- 2005) Analysing interaction in focus groups. In Drew, P., Raymond, G. and Weinberg, D. (eds) Talking Research. London: SAGE. (
- World Health Organization (2001) World Health Report 2001. Geneva: World Health Organization.